CREON
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency (EPI)
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Trial Timeline
May 6, 2020 → Sep 22, 2021
NCT ID
NCT04315311About CREON
CREON is a approved stage product being developed by AbbVie for Exocrine Pancreatic Insufficiency (EPI). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04315311. Target conditions include Exocrine Pancreatic Insufficiency (EPI).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05069597 | Approved | Completed |
| NCT04949828 | Pre-clinical | Completed |
| NCT04315311 | Approved | Withdrawn |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency (EPI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 33 |
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 77 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 52 |
| Pancrelipase + Placebo | AbbVie | Approved | 85 |
| Pancrelipase Capsules | AbbVie | Approved | 85 |
| Lipacreon | Viatris | Pre-clinical | 20 |